Dietary fructose is primarily metabolized in the liver. Here we demonstrate that, compared with normal hepatocytes, hepatocellular carcinoma (HCC) cells markedly reduce the rate of fructose metabolism and the level of reactive oxygen species, as a result of a c-Myc-dependent and heterogeneous nuclear ribonucleoprotein (hnRNP) H1-and H2-mediated switch from expression of the high-activity fructokinase (KHK)-C to the low-activity KHK-A isoform. Importantly, KHK-A acts as a protein kinase, phosphorylating and activating phosphoribosyl pyrophosphate synthetase 1 (PRPS1) to promote pentose phosphate pathway-dependent de novo nucleic acid synthesis and HCC formation. Furthermore, c-Myc, hnRNPH1/2 and KHK-A expression levels and PRPS1 Thr225 phosphorylation levels correlate with each other in HCC specimens and are associated with poor prognosis for HCC. These findings reveal a pivotal mechanism underlying the distinct fructose metabolism between HCC cells and normal hepatocytes and highlight the instrumental role of KHK-A protein kinase activity in promoting de novo nucleic acid synthesis and HCC development.
Dietary fructose, derived from fruits and vegetables and present in added sugars such as sucrose and high-fructose corn syrup, is metabolized primarily in the liver and epidemiologically linked with obesity and metabolic syndrome [1] [2] [3] . Fructose is metabolized by fructokinase (also known as ketohexokinase; KHK). KHK uses adenosine triphosphate (ATP) as a phosphate donor and phosphorylates fructose to produce fructose 1-phosphate (F1P). F1P is subsequently metabolized by aldolase B and triokinase to dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, which enter the later stages of glycolysis. Fructose catabolism initiated by KHK therefore bypasses important glycolytic regulatory steps in glycolysis that generate fructose 1,6-bisphosphate through the action of the energy-sensitive enzyme phosphofructokinase (PFK), resulting in greater lipogenesis than that resulting from glycolysis-regulated lipid production. In addition, fructose catabolism bypasses the glucose-6-phosphate and fructose-6-phosphate-derived pentose phosphate pathway (PPP), which produces ribose-5-phosphate (R5P) for de novo synthesis of nucleotides and nucleic acids 3, 4 ( Supplementary Fig. 1 ). Although glucose and fructose catabolism in a normal liver have been well studied, it is unknown whether these sugars are distinctly metabolized to promote development of hepatocellular carcinoma (HCC), one of the most aggressive cancers with a median survival time shorter than one year [5] [6] [7] . Regulation of mutually exclusive splicing of the adjacent exons 3C and 3A of the KHK gene by an unknown mechanism leads to alternative expression of the KHK-C and KHK-A isoforms, respectively 8, 9 . KHK-C, which is expressed primarily in the liver, has a much greater affinity and a lower Michaelis constant (K m ) for fructose than does KHK-A 10, 11 . KHK-C rapidly metabolizes fructose to F1P, resulting in transient depletion of intracellular phosphate and ATP 10 . Thus, KHK-C is considered the primary enzyme involved in fructose metabolism. In contrast, KHK-A is expressed at low levels in a wide range of tissues, and its physiological substrate remains unknown Tumour cells predominantly produce energy through a high rate of glycolysis followed by lactic acid fermentation in the cytosol, even in the presence of ample oxygen. This tumour-specific Warburg effect promotes tumour progression 15, 16 . The enhanced production of glycolytic intermediates thereby can be used for synthesis of cellular building blocks (nucleotides, amino acids and lipids) to meet the demands of cell proliferation. Phosphoribosyl pyrophosphate (PRPP) synthetases (PRPSs) are enzymes that catalyse the first and ratelimiting reaction for nucleotide synthesis, producing PRPP from R5P by transferring the β,γ-diphosphoryl moiety of ATP to the C1-hydroxy group of R5P ( Supplementary Fig. 1 ) 17, 18 . PRPP is then used for synthesis of purine and pyrimidine nucleotides, the pyridine nucleotide cofactors NAD and NADP, and the amino acids histidine (His) and tryptophan 19 . Human PRPSs have three isoforms that share very high sequence identity: PRPS1 and PRPS2 genes are expressed in a wide range of tissues, whereas PRPS3 is expressed specifically in the testis. PRPSs require Mg 2+ , sulfate (SO 4 2− ) and phosphate for enzymatic activity. Despite having a 94% amino acid sequence identity, PRPS1 and PRPS2 differ significantly in their regulation. PRPS1 is inhibited by the nucleotide biosynthesis products ADP, AMP and GDP, whereas PRPS2 is largely resistant to this feedback inhibition 20, 21 . Mutations of PRPS1, which reduced feedback inhibition of purine biosynthesis, were identified in relapsed childhood B cell acute lymphoblastic leukaemia 22 (ALL), whereas PRPS2 and enhanced PRPS2 expression were shown to be crucial for lymphoma and melanoma cell survival [23] [24] [25] . However, the mechanism through which the aberrant post-translational regulation of PRPS contributes to tumour development is unknown.
In this report, we demonstrate that HCC cells reduce the fructose metabolism rate, which is mediated by heterogeneous nuclear ribonucleoprotein (hnRNP) H1 and H2-dependent alternative splicing of the KHK gene by exon 3C exclusion and exon 3A inclusion, resulting in a switch from KHK-C to KHK-A expression. KHK-A acts as a protein kinase to phosphorylate and activate PRPS1 by prevention of inhibitory nucleotide binding and facilitation of ATP binding, leading to enhanced nucleic acid synthesis for tumorigenesis.
hnRNPH1/2 expression switches KHK-C expression to KHK-A expression in HCC cells
To determine whether normal hepatocytes and HCC cells differ in their fructose consumption, we cultured Hep3B and Huh7 HCC cells and normal hepatocytes in the presence of D- [5- 3 H]fructose tracer. Tumour cells had markedly reduced rates of fructose metabolism compared with the normal hepatocytes (Fig. 1a ). Immunoblot analysis with KHK isoform-specific antibodies revealed that Hep3B and Huh7 cells exclusively expressed the KHK-A isoform, whereas KHK-C was predominantly expressed in normal hepatocytes (Fig. 1b) . These results suggested an altered splicing of KHK pre-mRNA in HCC cells, which promotes expression of low-activity KHK-A rather than active KHK-C, contributing to reduced fructose metabolism in HCC cells. Consistent with a mechanism of aberrant splicing, quantitative PCR with reverse transcription (RT-PCR) analysis followed by exon 3C-specific digestion by the restriction enzyme BsmAI demonstrated that the KHK-A mRNA isoform was predominantly expressed in HCC cells, whereas normal hepatocytes primarily expressed KHK-C (Fig. 1c) . Consistent results were obtained by analyses of 30 paired human HCC and matched adjacent non-tumour tissue samples ( Fig. 1d and Supplementary Fig. 2a) . These results implicated an aberrant splicing change associated with hepatocellular transformation.
To identify the mechanism underlying KHK splicing, we synthesized biotin-labelled EI3A and EI3C RNA nucleotides spanning boundary regions of exons 3A-3 and 3C-3 with their adjacent introns. A pulldown assay of Hep3B cell lysates with these immobilized RNA nucleotides demonstrated that the EI3C but not the EI3A nucleotide was associated with major proteins with molecular masses of approximately 50,000 (M r 50K) identified as hnRNPH1 and hnRNPH2 through mass spectrometry (Fig. 1e ). HnRNPH1 and hnRNPH2 are RNA-binding proteins with wellestablished roles as sequence-specific repressors of splicing, and they recognize the GGGC/GGGA consensus sequence 26 . Analysis of the EI3C sequence revealed a GGGC motif adjacent to exon 3C (Fig. 1f top panel) . Mutation of G1 in this motif into C abolished the binding of hnRNPH1/2 to EI3C ( Fig. 1f bottom panel) . In addition, immunoprecipitation of hnRNPH1/2 and RT-PCR analysis of hnRNPH1/2-associated RNA demonstrated association of hnRNPH1/2 with an RNA fragment transcribed from exon 3C and the GGGC motif ( Supplementary Fig. 2b ). These results strongly suggested that hnRNPH1 and hnRNPH2 bind to the GGGC motif in the intron immediately adjacent to exon 3C-3 .
HnRNPH1 and hnRNPH2 are more than 98% homologous ( Supplementary Fig. 2c ), suggesting that they have functional redundancy. We depleted both hnRNPH1 and hnRNPH2 by expressing a short hairpin RNA (shRNA) against hnRNPH1/2 in Hep3B and Huh7 cells (Fig. 1g) . RT-PCR analyses demonstrated that hnRNPH1/2 depletion resulted in a switch of expression of KHK from BsmAI-resistant KHK-A to BsmAI-sensitive KHK-C (Fig. 1h  left panel) , and immunoblot analyses detected altered corresponding protein expression (Fig. 1h right panel) . These results indicated that binding of hnRNPH1/2 to the exon 3C-3 /intron region leads to exclusion of exon 3C and inclusion of exon 3A for KHK-A expression.
The 5 and 3 splicing sites of genes are recognized by U1-type small nuclear ribonucleic protein (U1 snRNP) and U2AF, respectively. HnRNPH1 and hnRNPH2 repress a splicing site and promote alternative 5 splicing selection 26, 27 . We next synthesized premRNAs by transcribing a plasmid DNA carrying the T7 promoter and a truncated adenovirus 2 major late (AdML) transcription unit (exons 1 and 2), in which we replaced exon 1 and the intron with KHK exon 3C and its downstream intron with or without the G1C mutation ( Supplementary Fig. 2d left panel) . Incubation of these pre-mRNAs with nuclear extracts of Hep3B cells with or without hnRNPH1/2 depletion and PCR analysis demonstrated that G1C mutation and hnRNPH1/2 depletion promoted the splicing and removal of the intron ( Supplementary Fig. 2d right panel) . These results further supported that hnRNPH1/2 binding blocks the recognition of the exon 3C 5 splice site (immediately downstream from exon 3C), which prevents recognition of exon 3C and favours the inclusion of exon 3A.
To further validate this finding in vivo, we transfected Hep3B cells with a plasmid containing a minigene including the gene fragment of KHK from exon 2 to exon 4 with or without G1C mutation (Fig. 1i  top panel Fig. 2a) . The KHK-A/KHK-C ratios in HCC and matched non-tumour liver tissue samples obtained from n = 30 patients were calculated. A paired two-tailed Student's t-test was used. P < 0.0001. (e) The indicated streptavidin bead-immobilized biotinlabelled RNA probes (60 nucleotides) spanning the EI3A and EI3C splice sites (top panel) were incubated with Hep3B cell lysates. The associated proteins were separated using SDS-PAGE and stained with Coomassie brilliant blue (bottom panel). The indicated protein band was excised for mass spectrometric analysis and identified as hnRNPH1/2 (peptide hits, 66; P < 0.0001). P values were calculated using a paired Student's t-test. (f) The putative hnRNPH1/2-binding residues (red) in the EI3C sequence (exon 3C and its 3 adjacent intron) are shown (top panel). Streptavidin bead-immobilized WT or mutated EI3C RNA was incubated with Hep3B cell lysates, which was followed by immunoblot analyses with the indicated antibodies (bottom panel). (g,h) The indicated cells did or did not express hnRNPH1/2 shRNA (g); the RT-PCR products were digested by BsmAI (h left panel); immunoblot analyses were performed using the indicated antibodies (g,h right panel). (i) Schematic diagram of the KHK minigene constructs with or without G1C mutation (top panel), which were expressed in Hep3B cells. The RT-PCR products were digested by BsmAI and resolved on an agarose gel (bottom panel). BGH, bovine growth hormone polyadenylation signal. In b,c, and e-i, data represent one out of three experiments. Unprocessed original scans of blots are shown in Supplementary Fig. 7 .
exon 3C, whereas KHK minigene expression with G1C mutation led to inclusion of exon 3C but not exon 3A in mRNA (Fig. 1i bottom  panel) . These results provided additional evidence supporting the finding that binding of hnRNPH1/2 to the GGGC motif in the intron adjacent to KHK exon 3C leads to exclusion of exon 3C and inclusion of exon 3A. c-Myc-enhanced hnRNPH1/2 expression switches KHK-C expression to KHK-A expression in HCC cells It was reported that c-Myc, which is commonly overexpressed in primary and advanced HCC, regulates the expression of hnRNPH1 by binding to a noncanonical E-box region in the promoters of the hnRNPH1 gene 28, 29 . Consistent with this observation, chromatin immunoprecipitation (ChIP) showed that c-Myc bound to the promoter regions of both hnRNPH1 and hnRNPH2 in Hep3B and Huh7 cells (Fig. 2a) and shRNA-mediated depletion of c-Myc reduced expression of hnRNPH1/2 ( Fig. 2b) . Importantly, c-Myc depletion resulted in a concomitant decrease in KHK-A mRNA and increase in KHK-C mRNA expression with corresponding protein expression (Fig. 2c ). In addition, overexpression of c-Myc in normal hepatocytes resulted in increased expression of hnRNPH1/2 and KHK-A and decreased KHK-C expression (Fig. 2d) . These results indicated that c-Myc upregulates hnRNPH1/2 expression, which in turn promotes a switch from KHK-C to KHK-A expression.
KHK-A phosphorylates PRPS1 at Thr225
KHK-A poorly phosphorylates fructose, and its physiological substrate remains unidentified 10 . To this end, we immunoprecipitated KHK-C and KHK-A from Hep3B cells followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Figure 3a shows that a protein (about M r 35K) was specifically associated with KHK-A but not KHK-C. Mass spectrometric analysis identified this protein as PRPS1. Immunoprecipitation analyses revealed that Flagtagged KHK-A but not KHK-C binds to endogenous PRPS1 (Fig. 3b) . We also detected binding of endogenous KHK-A to endogenous PRPS1 (Fig. 3c ). In addition, purified GST-KHK-A directly bound to purified His-PRPS1, but not PRPS2 ( Supplementary Fig. 3a) , and the expression of PRPS2 was barely detectable in normal hepatocytes and HCC cells ( Supplementary Fig. 3b ). To uncover the interaction site of KHK-A, we mutated hydrophobic surface residues among 45 amino acids coded by exon 3A. Only mutation of L83A was found to abolish the interaction between KHK-A and PRPS1 detected through co-immunoprecipitation assay in vivo (Fig. 3d) , which was further validated using a glutathione S-transferase (GST) pulldown assay in vitro (Fig. 3e) . In contrast, KHK-C, which shares 37.8% protein sequence identity comparing the exon 3A-and 3C-coding regions, failed to directly bind to PRPS1 (Fig. 3e) . These results indicated that Leu83 of KHK-A interacts directly with PRPS1.
KHK-A, which has a greatly reduced affinity for fructose (K m : 9.41 mM) and does not efficiently use ATP to phosphorylate fructose 10 , interacts with PRPS1 with a much higher affinity 564 0 400 600 800 1,000
Mass (m/z) Mr (K) (K m : 0.228 µM) (Supplementary Fig. 3c ). Of note, the intracellular concentration of PRPS-1 is about 1.8 µM (Supplementary Fig. 3d ), which is much higher than the K m of KHK-A for PRPS1. This finding led us to examine whether KHK-A can function as a protein kinase to phosphorylate PRPS1 rather than fructose in HCC cells. We performed an in vitro phosphorylation assay by mixing purified recombinant KHK-A and PRPS1 ( Supplementary Fig. 3e ) in the presence of ATP. Liquid chromatography-coupled Orbitrap tandem mass spectrometric analysis demonstrated that KHK-A phosphorylates PRPS1 at Thr225 (Fig. 3f) . The phosphorylation of PRPS1, but not PRPS2 (Supplementary Figs 3f,g ), by WT KHK-A, but not KHK-A L83A (Fig. 3g, left panel) , was also detected using autoradiography with [γ- 32 P]ATP and a specific anti-phospho-PRPS1 Thr225 antibody. In addition, we created a KHK-A ATP-binding site mutation by converting the conserved Gly257 in the ATP-γ-phosphate binding motif (GAGD) to arginine 30 . KHK-A G257R, which was still able to bind to PRPS1 (Supplementary Fig. 3h ), lost its binding to ATP (Supplementary Fig. 3i ) and failed to phosphorylate PRPS1 at Thr225 (Fig. 3g, right panel) . As expected, KHK-C did not phosphorylate PRPS1 (Supplementary Fig. 3j ). These results indicated that the interaction between KHK-A and PRPS1 and the ATP-binding ability of KHK-A are required for PRPS1 phosphorylation.
We next expressed KHK shRNA and reconstituted the expression of RNA interference-resistant (r) WT KHK-A, rKHK-A L83A or WT rKHK-C in both Hep3B and Huh7 cells (Fig. 3h) . Immunoblot analysis demonstrated that KHK depletion abrogated PRPS1 Thr225 phosphorylation, which was rescued by expression of WT rKHK-A but not WT rKHK-C or rKHK-A L83A (Fig. 3i ). In line with this finding, PRPS1 T225A expressed in Hep3B cells was resistant to phosphorylation (Fig. 3j) . Notably, PRPS1 Thr225 phosphorylation was not affected by increased concentrations of fructose (up to 20 mM) in cultured medium, further demonstrating the high affinity of KHK-A for PRPS1 ( Supplementary Fig. 3k ). These results indicated that KHK-A phosphorylates PRPS1 at Thr225.
KHK-A-mediated PRPS1 phosphorylation activates PRPS1
The activators (sulfate and phosphate) and inhibitors (ADP, AMP, IMP, and GMP) of PRPS1 compete for the same allosteric regulatory site for regulation of PRPS1 activity in vitro 21, 31, 32 . Our structure analysis of PRPS1 revealed that Thr225 of PRPS1 is in the allosteric site ( Fig. 4a) and that Thr225 phosphorylation may physically block the binding of ADP to PRPS1. To examine this possibility, we mixed purified His-PRPS1 proteins with GST-KHK-A to phosphorylate PRPS1 in vitro (Fig. 4b left panel) followed by incubation of [ 14 C]ADP. Phosphorylation of WT PRPS1, but not the PRPS1 T225A mutant, largely blocked the binding of ADP to PRPS1 (Fig. 4b right panel) . These results strongly suggested that PRPS1 Thr225 phosphorylation sterically blocked the access of the allosteric site of PRPS1 to ADP. In line with this finding, we revealed that PRPS1 Thr225 phosphorylation significantly increased PRPS1 activity (Fig. 4c) . In addition, inclusion of ADP at a high dose, which reduced phosphate-dependent PRPS1 activity ( Supplementary Fig. 4a ), had a limited effect on the activity of phosphorylated PRPS1 (Fig. 4c) . Similar results were also observed using AMP, IMP and GMP, which did not affect the phosphorylated PRPS activity, but inhibited phosphate-dependent PRPS1 activity to a variable extent ( Supplementary Fig. 4b,c) .
To further understand how PRPS1 is distinctly regulated in normal hepatocytes and HCC cells, we immunoprecipitated PRPS1 and found that PRPS1 from normal hepatocyte was activated by phosphate in a dosage-dependent manner (Fig. 4d left panel) . In contrast, phosphorylated PRPS1, which had high activity and made up more than 90% of the total PRPS1 in Hep3B cells (Supplementary Fig. 4d ), was resistant to regulation by phosphate (Fig. 3d right panel) . These results strongly suggested that PRPS1 activity in normal cells is dynamically regulated and can be activated by phosphate. Activated PRPS1 increases the production of nucleotides, such as ADP, AMP, IMP and GMP, which will inhibit PRPS1 in a feedback manner. In contrast, phosphorylation of PRPS1 by KHK-A in HCC cells abrogates the feedback inhibition by these nucleotides and results in a constantly high level of PRPS1 activity.
Given that regulation of the allosteric site of PRPS1 affects the binding of ATP to PRPS1 and subsequently its activation 21, 31, 32 , we performed an in vitro ATP-binding assay and demonstrated that phosphorylation of PRPS1 Thr225 greatly enhanced the binding of [γ-
32 P]ATP to WT PRPS1 compared with non-phosphorylated PRPS1 and the PRPS1 T225A mutant (Fig. 4e) .
To determine the role of KHK-A in regulation of PRPS1 in HCC cells, we immunoprecipitated Flag-PRPS1 from Hep3B cells and found that KHK depletion reduced the Thr225 phosphorylation ( Fig. 4f left panel) and activity ( Fig. 4f right panel) of PRPS1, and this inhibitory effect was rescued by reconstituted expression of WT rKHK-A but not rKHK-A L83A or WT rKHK-C (Fig. 4f) . In addition, immunoprecipitated Flag-PRPS1 T225A, which was resistant to phosphorylation ( Fig. 4e) , had a much lower activity than WT PRPS1 (Fig. 4g) . These results indicated that KHK-A phosphorylates and activates PRPS1.
KHK-A promotes de novo nucleic acid synthesis and reduces ROS level
To determine the role of KHK-A in PRPS1-dependent nucleic acid synthesis, we incubated Hep3B and Huh7 cells with D- [6- 14 C]glucose and revealed that hnRNPH1/2 depletion largely reduced glucosederived production of both [ 14 C]RNA (Fig. 5a ) and the RNA precursor inosine monophosphate (IMP) (Supplementary Fig. 5a ). In addition, reconstituted expression of rKHK-A L83A and WT rKHK-C failed to rescue this effect ( Fig. 5b and Supplementary Fig. 5b ).
PRPS1 and PRPS2 have more than 94% homology and share a conserved Thr225. In line with the finding that the HCC cell lines primarily express PRPS1 with barely detectable PRPS2 mRNA ( Supplementary Fig. 3b ), PRPS1 depletion in Hep3B and Huh7 cells by expressing a PRPS1 shRNA greatly reduced the total expression of PRPS proteins, as detected by immunoblot analyses with an antibody recognizing both PRPS1 and PRPS2 (Fig. 5c left panel) . Notably, PRPS1 depletion inhibited the production of RNA and IMP, which was rescued by reconstituted expression of WT rPRPS1 but not rPRPS1 T225A (Fig. 5c right panel and Supplementary Fig. 5c ). These results indicated that KHK-A-dependent PRPS1 phosphorylation promotes glucose-derived de novo nucleotide and nucleic acid synthesis.
PRPS1 Thr225 phosphorylation abrogates the allosteric feedback inhibition by ADP and other nucleotides. As expected, reconstituted expression of the active PRPS1 A190T mutant, which lost the binding of the nucleotide inhibitors at the allosteric sites and was identified in relapsed childhood B cell ALL 22 , had a comparable IMP production compared to expression of WT PRPS1 (Supplementary Fig. 5c ), which is predominately phosphorylated in Hep3B cells. In line with the 0 * * * * # # * finding that PRPS1 activity in normal cells but not HCC cells is regulated by phosphate (Fig. 4d) , increased phosphate concentration in the culture medium enhanced de novo RNA production in normal hepatocytes, but not in Hep3B cells (Fig. 5d) . However, this increased RNA production in normal hepatocytes was transient and downregulated after prolonged incubation with phosphate, suggesting a negative feedback inhibition of PRPS1 by newly synthesized nucleotides. These results indicate that PRPS1-dependent nucleic acid synthesis in normal hepatocytes is dynamically regulated; in contrast, cancer cells acquire a constantly high level of PRPS1 activity for nucleic acid production. Fructose metabolism reduces intracellular phosphate and ATP levels and generates many folds more reactive oxygen species (ROS) than glucose metabolism, which are disadvantages to cell growth and survival 10, [33] [34] [35] . The switch from high-activity KHK-C expression to low-activity KHK-A expression may prevent such fructose metabolism-induced disadvantages. To test this hypothesis, we cultured Hep3B cells with reconstituted expression of KHK-C or KHK-A in the presence or absence of fructose. We found that fructose significantly reduced the levels of ATP ( Supplementary  Fig. 5d ) and phosphate ( Supplementary Fig. 5e ) and increased ROS levels in Hep3B cells expressing KHK-C but not in Hep3B cells expressing KHK-A (Fig. 5e) . Taken together, these results indicated that aberrant splicing of the KHK transcript in HCC cells results in enhanced nucleic acid synthesis and inhibited the effect of fructose metabolism on the regulation of phosphate, ATP and ROS.
KHK-A-mediated PRPS1 phosphorylation promotes tumorigenesis and is associated with HCC pathogenesis Enhanced de novo nucleic acid synthesis and ATP production and reduced ROS level promote tumour cell proliferation. As expected, hnRNPH1/2 depletion greatly inhibited the proliferation of Hep3B and Huh7 cells (Fig. 6a) . In addition, compared with the HCC cells with reconstituted expression of rKHK-A, rPRPS1 and rPRPS1 A190T, the cells with KHK depletion or reconstituted rKHK-A L83A or WT rKHK-C expression (Fig. 6b ) and the cells with PRPS1 depletion or reconstituted expression of rPRPS1 T225A expression (Fig. 6c) exhibited much reduced proliferation without obviously altered apoptosis (Supplementary Fig. 6a ). Furthermore, an increased fructose concentration in the medium inhibited the proliferation of Hep3B with reconstituted expression of rKHK-C, but not rKHK-A, and this inhibition was partially alleviated by treatment with the reducing reagent N -acetylcysteine (NAC; Supplementary Fig. 6b ). (f) c-Myc, hnRNPH1/2 and KHK-A expression levels and PRPS1 Thr225 phosphorylation levels in HCC and matched non-tumour liver samples were obtained from n = 90 patients. The data represent the mean ± s.d. The indicated staining scores in HCC and matched non-tumour liver samples were compared using a paired Student's t-test. * P < 0.001. (g) Kaplan-Meier plots of the overall survival rates in the patients (n = 90) with HCC in the groups with high (staining score, 5-8.0) and low (staining score, 0-4.0) expression of c-Myc, hnRNPH1/2 and KHK-A and phosphorylation of PRPS1 Thr225. The P values were calculated using the log-rank test. (h) A mechanism of KHK-A-promoted de novo nucleotide synthesis. c-Myc enhances the expression of hnRNPH1 and hnRNPH2, which bind to the exon 3C-3 /intron region of KHK, leading to alternative splicing of KHK pre-mRNA for KHK-A expression and reduced fructose metabolism. KHK-A phosphorylates and activates PRPS1, resulting in enhanced production of nucleotide and nucleotide acid derived from glycolysis and promotion of hepatocellular tumorigenesis.
We next intrahepatically injected Huh7 cells depleted of hnRNPH1/2, KHK or PRPS1 into nude mice. Depletion of these proteins markedly inhibited hepatocellular tumour growth (Fig. 6d) . Notably, reconstituted expression of WT rKHK-A or WT rPRPS1, but not rKHK-A L83A, WT rKHK-C or rPRPS1 T225A, rescued tumour growth (Fig. 6d) . Immunoblot analysis demonstrated strong phosphorylation of PRPS1 Thr225 and high expression of proliferating cell nuclear antigen (PCNA) in the tissue of tumours derived from Hep3B cells with reconstituted expression of WT rKHK-A or rPRPS1 compared with tumour tissues with reconstituted expression of rKHK-A L83A, WT rKHK-C or rPRPS1 T225A ( Supplementary  Fig. 6c ). These results indicated that hnRNPH1/2-regulated KHK-A expression and KHK-A-mediated PRPS1 phosphorylation promote HCC development.
To determine the clinical relevance of our findings, we performed immunohistochemical analysis of 90 primary HCC samples and matched non-tumour liver tissue samples with validated antibodies recognizing c-Myc, hnRNPH1/2, KHK-A and phosphorylated PRPS1 Thr225 proteins (Supplementary Fig. 6d ). We revealed that the levels of c-Myc, hnRNPH1/2 and KHK-A expression and PRPS1 Thr225 phosphorylation were markedly higher in HCC samples than in matched non-tumour tissue samples (Fig. 4e,f) and correlated with each other in HCC samples (Supplementary Fig. 6e) .
We accessed the survival durations in the 90 HCC patients, all of whom underwent standard surgical resection of HCC. Figure 6g shows that high levels of c-Myc, hnRNPH1/2, KHK-A and PRPS1 Thr225 phosphorylation in HCC samples correlated with poor overall survival durations in the patients and vice versa. In addition, expression levels of these proteins were independent prognostic factors for overall survival (Supplementary Table 1) . These results supported a critical role for KHK-A-dependent PRPS1 phosphorylation in the clinical aggressiveness of human HCC.
DISCUSSION
Fructose is a major form of dietary sugar that is catalysed in the liver for lipogenesis [1] [2] [3] . However, compared with normal liver cells, HCC cells have much lower levels of fructose metabolism, which may prevent enhanced ROS production and uncontrolled lipid production 3, 4, 33 . The low fructose metabolism is mediated by hnRNPH1/2 expression induced by c-Myc, whose overexpression is prevalent in HCC cells 36 . We demonstrated that hnRNPH1/2 bind to a consensus sequence located immediately adjacent to the exon 3C 5 splice site. Mutation of the consensus site or hnRNPH1/2 depletion results in switching from KHK-A to KHK-C isoform expression. These results indicate that hnRNPH1/2 control the outcome of a mutually exclusive splicing event by binding and repressing the recognition of exon 3C to allow exon 3A inclusion by potentially inducing intronic structures conducive to inclusion of exon 3A and exclusion of exon 3C 26, 27 . Tumour cells have enhanced glycolysis for anabolic synthesis. In the present study, we identified a critical mechanism underlying glucose-derived de novo nucleic acid synthesis through KHK-Amediated phosphorylation and activation of PRPS1 (Fig. 6h) . The understanding that an hnRNPH1/2-dependent switch from KHK-C to KHK-A expression and KHK-A-mediated phosphorylation of PRPS1 are required for HCC development and that PRPS1 Thr225 phosphorylation and hnRNPH1/2 expression correlate with prognosis for HCC may provide a molecular basis for improved diagnosis and treatment of HCC.
In summary, our findings demonstrated that HCC cells have a distinct regulatory mechanism of fructose catabolism that differs from the mechanisms in their normal counterparts. We showed that coordinated regulation of glucose and fructose metabolism in supporting HCC cell proliferation by KHK-A is essential for HCC development. The demonstration that KHK-A functions as a protein kinase highlights the dual roles of KHK-A as both a metabolic enzyme and a protein kinase in cell metabolism and proliferation, and greatly impacts the understanding of protein enzymes with multiple roles in controlling cellular functions.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3338

Materials.
Rabbit polyclonal antibodies against KHK-A, KHK-C and phospho-PRPS1 Thr225 were obtained from Signalway Antibody. For the antibodies recognizing KHK-A and KHK-C, a peptide containing exon 3A-coded regions (72-VLDDLRRYSVDLRYTVFQTTGSVPIATVIINEASGSRTILYYDR-115) or exon 3C-coded regions (72-LVADFRRRGVDVSQVAWQSKGDTPSSCCIINNSNGNRT IVLHDT-115), was injected into rabbits. The rabbit serum was collected and purified by an affinity column conjugated with exon 3A-or exon 3C-peptide, followed by elution and concentration. For the antibody recognizing phospho-PRPS1 Thr225, a peptide containing PRPS1 pThr225 was injected into rabbits. The rabbit serum was collected and purified using an affinity column conjugated with non-phosphorylated PRPS1 Thr225 peptide to exclude the antibodies recognizing non-phosphorylated PRPS1, followed by an affinity column conjugated with phosphorylated PRPS1 Thr225 peptide to bind to and purify the phospho-PRPS1 Thr225 antibody. The phospho-PRPS1 Thr225 antibody was then eluted and concentrated. A working concentration of 1 µg ml −1 and 5 µg ml −1 was used for immunoblotting and immunohistochemical staining, respectively.
Rabbit polyclonal antibodies recognizing hnRNPH1/2 and c-Myc, and mouse monoclonal antibody recognizing V5 tag were obtained from Abcam. Monoclonal antibodies against GST, tubulin, PRPS1/2 and pan-KHK-A/C were purchased from Santa Cruz Biotechnology. Active recombinant human IMPDH2 (inosine monophosphate dehydrogenase 2) protein, a mouse monoclonal antibody for Flag, anti-Flag M2 agarose beads, streptavidin-conjugated agarose beads, fructose, EGTA, ADP, NADH, IMP, AMP, GMP, N -acetyl-L-cysteine (NAC), phosphoenolpyruvate, pyruvate kinase, myokinase and lactic dehydrogenase were purchased from Sigma. HyFect transfection reagents were from Denville Scientific. Normal human hepatocytes and Williams' Medium E were purchased from Invitrogen. Synthesized biotinylated RNA containing exon 3A and exon 3C and their adjacent intron sequences was purchased from Selleck Chemicals. [γ-
32 P]ATP was purchased from MP Biomedicals. D- [5- 3 H]fructose and D-[6-14 C]glucose were purchased from American Radiolabeled Chemicals. [8- 14 C]ADP was purchased from Perkin Elmer. Scintillation vials were purchased from Thermo Fisher Scientific. Streptavidin beads were purchased from Pierce.
Supplementary Table 2 contains detailed information on the used antibodies.
Cell lines and cell culture conditions. Hep3B and Huh7 cells were from ATCC and were maintained in Dulbecco's modified Eagle's medium supplemented with 10% dialysed bovine calf serum (HyClone). Normal human hepatocytes were maintained in Williams' Medium E (Invitrogen). No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample. Cell lines were authenticated by short tandem repeat profiling and were routinely tested for mycoplasma contamination.
In vitro kinase assay. Kinase reactions were performed as described previously 37 . In brief, bacterially purified recombinant KHK-A or KHK-C (10 ng) was incubated with PRPS1 (100 ng) in 25 µl of kinase buffer (50 mM Tris-HCl, pH 7.5, 100 mM KCl, 50 mM MgCl 2 , 1 mM Na 3 VO 4 , 1 mM dithiothreitol (DTT), 5% glycerol, 0.2 mM ATP, 10 µCi of [γ-32 P]ATP) at 25 • C for 1 h. The reactions were terminated with the addition of SDS-PAGE loading buffer and heated to 100 • C. The reaction mixtures were then subjected to SDS-PAGE analysis.
Purification of recombinant proteins. His-KHK-A, His-KHK-C, GST-KHK-A, GST-KHK-C, His-PRPS1 and His-PRPS2 were expressed in bacteria and purified as described previously 38 . Briefly, BL21(DE3)pLysS cells expressing (His) 6 -or GSTtagged KHK-A, KHK-C, PRPS1 and PRPS2 proteins were cultured in 250 ml LB medium and were treated with IPTG for 16 h at 30 • C before lysis by sonication. For (His) 6 -tagged proteins, cell lysates were loaded onto a Ni-NTA column (GE Healthcare Life Sciences) followed by washing with five column volumes of 20 mM imidazole and subsequent elution with 250 mM imidazole. For GST-tagged proteins, cell lysates were loaded onto a GSTrap HP column (GE Healthcare Life Sciences) followed by washing with five column volumes of PBS and subsequent elution with 10 mM reduced glutathione.
The proteins in 10 kDa spin columns were desalted by washing twice with ice-cold PBS. We then loaded the proteins onto a HiPrep 16/60 Sephacryl S-200 HR gel filtration column (GE Healthcare Life Sciences) to remove the contaminated proteins. Purification efficiency was examined by SDS-PAGE and colloidal Coomassie blue (G-250) staining with superior sensitivity that detects as low as 1 ng protein per band 39 .
Immunoprecipitation and immunoblot analysis. Extraction of proteins from cultured cells using a modified buffer was followed by immunoprecipitation and immunoblot analyses with corresponding antibodies as described previously 40 . The band intensity was quantified using the Image Lab software program (Bio-Rad).
Transfection. Cells were plated at a density of 4 × 10 5 per 60-mm dish 18 h before transfection. Transfection of cells was performed as described previously 38 .
Fructose metabolic rate assay. 
RT-PCR.
Total RNA was extracted from cultured HCC cells and human HCC samples using TRIzol (Invitrogen) according to the manufacturer's instructions. Total RNA (1 µg) was used for each sample in a 20 µl reaction using an iScript cDNA synthesis kit (Bio-Rad). One microlitre of the cDNA library was used in a 50 µl PCR. One microgram of the PCR products was digested with BsmAI, and the products of digestion were resolved on a 2% agarose gel. The intensity of the bands in the agarose gel was quantified using the Image Lab software program (Bio-Rad). Human KHK forward and reverse primers were used in the PCRs. For distinguishing the PRPS1 and PRPS2 cDNA, one microgram of the PCR products was digested by HindIII, and the products of digestion were resolved on a 2% agarose gel. Human PRPS forward and reverse primers were used in the PCRs. For in vivo splicing assays, KHKmini forward and reverse primers were used in the PCRs. For in vitro splicing assays, AdML forward and reverse primers were used in the PCRs.
Supplementary Table 3 contains detailed information on the primer sequences.
RNA affinity binding assay. The RNA affinity binding assay was performed as described previously 41 with some modifications. 5 -biotinylated EI3A (−30 to +30) and EI3C (−30 to +30) RNA oligonucleotides were purchased from Midland Certified Reagent Company. One nanomole of both biotinylated RNA oligonucleotides was bound with 100 µl of streptavidin-conjugated agarose beads in 500 µl of binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM ethylenediaminetetraacetic acid, 2 M NaCl) overnight at 4 • C with rotation. The beads were washed twice with binding buffer and twice with buffer D (920 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM ethylenediaminetetraacetic acid, 0.5 mM DTT).
A nuclear extract mixture was prepared in a 500 µl volume (10 mM HEPES, pH 7.9, 10% glycerol, 50 mM KCl, 2 mM MgCl 2 , 0.75 mM ATP, 25 mM creatine phosphate, 0.1 mM ethylenediaminetetraacetic acid, 0.25 mM DTT, 30 µg of Escherichia coli transfer RNA) containing 125 µl of a Hep3B nuclear extract and preincubated at 30 • C for 10 min. RNA-immobilized beads were mixed with a preincubated nuclear extract mixture and incubated at 30 • C for 30 min with constant rotation. After RNA and protein binding, beads were washed with buffer D twice and buffer D without glycerol twice and eluted by adding 40 µl of Laemmli sample buffer and boiled for 5 min. Twenty-microlitre aliquots of the eluted bound proteins were resolved using 10% SDS-PAGE followed by Coomassie brilliant blue staining, and the protein bands were excised for mass spectrometric analysis.
Crosslinking and RNA immunoprecipitation. RNA immunoprecipitation was performed as described previously 42 with some modifications. Briefly, following ultraviolet crosslinking, Hep3B cells were collected, and nuclear extracts were prepared and sonicated. Protein A-Sepharose beads (Sigma) were incubated with a control rabbit IgG antibody or an anti-hnRNPH1/2 antibody for 4 h at 4 • C. Antibody-conjugated beads were washed twice with lysis buffer followed by incubation with precleared lysates at 4 • C overnight. After washing the beads with lysis buffer three times, one-quarter volume of total beads was eluted in SDS sample buffer for immunoblot analysis to monitor hnRNPH1/2 immunoprecipitation efficiency. The remaining beads were incubated with lysis buffer in the presence of RNase-free DNase (QIAGEN) for 15 min at 37 • C followed by incubation with 50 µg of proteinase K (Sigma) for 15 min at 37 • C. Coimmunoprecipitated RNA was then extracted using TRIzol and used for RT-PCR analysis. The primers (hnRNPH1/2-binding forward and hnRNPH1/2-binding reverse) were used in the PCRs.
Mass spectrometric analysis. An in vitro KHK-phosphorylated sample of purified PRPS1 was digested in-gel in 50 mM ammonium bicarbonate buffer containing RapiGest (Waters Corporation) overnight at 37 • C with 200 ng of modified sequencing-grade trypsin (Promega). The digested samples were analysed using high-sensitivity liquid chromatography tandem mass spectrometry with an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). Proteins were identified by searching the fragment spectra against the Swiss-Prot protein database (EBI) using the Mascot search engine (version 2.3; Matrix Science) via the Proteome Discoverer software program (version 1.4; Thermo Fisher Scientific). Phosphopeptide matches were analysed using the phosphoRS algorithm implemented in Proteome Discoverer and manually curated 43 .
GST pulldown assay. Glutathione agarose beads were incubated with purified protein for 12 h. The beads were then washed with a lysate buffer three times.
Cell proliferation assay. A total of 1 × 10 5 cells were plated and counted three days after seeding in Dulbecco's modified Eagle's medium with 10% bovine calf serum. The data are presented as the mean ± standard deviation (s.d.) from three independent experiments. KHK minigene construction. A KHK minigene containing exons 2, 3A, 3C and 4 and introns adjacent to exons 3A and 3C was amplified from genomic DNA from Hep3B cells using a Pfu PCR kit (Promega) for 35 cycles at an annealing temperature of 58 • C and a 150 s extension time. The KHK-specific primers were E2F and E4R with NheI and XbaI overhangs. The resulting PCR products were gelpurified, digested and subcloned into pcDNA3.1 (Invitrogen). The ligation reaction was transformed into TOP10 competent cells. Plasmid DNA was prepared, and the constructed vectors were confirmed using restriction digests and sequencing.
DNA constructs and mutagenesis. PCR-amplified human KHK-A, KHK-C and PRPS1 were cloned into a pCold I, pGEX-4T-1, pcDNA 3.1 or pET22b+ vector. pcDNA3.1-Flag-KHK-A L73A, pcDNA3.1-Flag-KHK-A V81A, pcDNA3.1-Flag-KHK-A L83A, pcDNA3.1-Flag-KHK-A V87A, pcDNA3.1-Flag-KHK-A I96A, pcDNA3.1-Flag-PRPS1 T225A, pcDNA3.1-V5-PRPS1 T225A, pcDNA3.1-V5-PRPS1 A190T, pcDNA3.1-V5-rKHK-A L83A, pcDNA3.1-KHK minigene G1C, pGEX-4T-1-KHK-A L83A and pCold-I-PRPS1 T225A were constructed using a QuikChange site-directed mutagenesis kit (Stratagene). pcDNA3.1 V5 rKHK contains nonsense mutations of G1084A, T1087C and C1090A. pcDNA3.1 V5 rPRPS1 contains nonsense mutations of A568C, T571C, T574C and T577C. The pGIPZ vector was used for construction of the control shRNA and shRNAs for KHK, PRPS1, c-Myc and hnRNPH1/2.
Supplementary Table 3 contains detailed information on the shRNA-targeted nucleotide sequences of the indicated genes.
In vivo and in vitro splicing assays. WT and mutated minigene vectors were transfected into Hep3B cells. Twenty-four hours after transfection, cells were collected, and the KHK-A/KHK-C mRNA ratio was analysed using RT-PCR followed by BsmAI digestion of PCR products. In vitro splicing substrates were constructed by replacing the first exon and downstream intronic sequence of AdML pre-mRNA with KHK exon 3C and the downstream intron 3 sequence with or without a mutated hnRNPH1/2-binding site. Pre-mRNA substrates were synthesized through in vitro transcription using T7 RNA polymerase (Promega) following the product's protocol. In vitro splicing of the WT and mutated pre-mRNA was carried out using Hep3B nuclear extracts.
ChIP assay. ChIP was performed using the SimpleChIP Enzymatic Chromatin IP kit (Cell Signaling Technology). Chromatin prepared from cells in a 10-cm dish was used to determine total DNA input and for overnight incubation with specific antibodies or normal mouse IgG. The human hnRNPH1 and hnRNPH2 promoterspecific primers (forward and reverse) were used in PCR.
